SLU-PP-332 Results Timeline: What Studies Measured, and When

A "results timeline" for a research compound is really a question about study design: at which point after dosing did investigators take a measurement, and what did that measurement capture? For SLU-PP-332, that question has a narrow answer, because the published record summarised here is preclinical and pharmacological rather than clinical. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing below describes what a person would experience at any week, and no dosing schedule, protocol or timing guidance is provided.

What the Timeline Question Actually Asks

In peptide and small-molecule research, three different kinds of outcome move on three different clocks. Molecular readouts — gene transcription, receptor occupancy, mitochondrial biogenesis markers — are typically the earliest measurements taken. Functional readouts, such as treadmill or running-wheel performance, require repeated testing and therefore sit further out. Tissue-level and disease-model readouts, such as organ histology or inflammatory burden in an aging model, sit furthest out because the biology being measured changes slowly.

When someone asks "how long does SLU-PP-332 take to work," they are usually asking about the second and third tiers. The verified literature covered here reports findings from those tiers in animal and chemical systems, but it does not translate them into a human week-by-week schedule, and this page does not attempt that translation either.

Where the Evidence Stands: Preclinical, Not Clinical

The most important timeline fact is a negative one. The citation set used on this page contains no human clinical trial of SLU-PP-332, and therefore no reported outcomes at 4, 8 or 12 weeks in people. A 2026 review in Revista médica de Chile discussed pharmacological activation of ERRα/β/γ as an exercise mimetic and its potential therapeutic applications, framing the field as one of potential rather than established clinical use (PMID 42024694). The word "potential" in that review's own framing is the clearest available signal about where the evidence base sits.

A 2026 paper in the International Journal of Biological Macromolecules described chemical optimization of the exercise mimetic SLU-PP-332 and reported that this optimization enabled insight into estrogen-related receptor signaling (PMID 41850449). Work of that kind — medicinal chemistry aimed at improving a scaffold — is characteristic of a compound still in the discovery and lead-optimisation stage, not one moving through dated clinical endpoints.

What Each Verified Paper Measured

The table below summarises the measurement domain of each paper in the verified set and the timeline tier it belongs to. Where a paper's abstract-level scope does not specify dosing duration, that is stated rather than estimated.

Tier one: molecular and chemical characterisation

The earliest measurements in this research family are not measured in weeks at all — they are measured in receptor pharmacology. The 2026 optimization paper reported that modifying the SLU-PP-332 scaffold produced insight into estrogen-related receptor signaling (PMID 41850449). These experiments answer questions about potency and selectivity across receptor subtypes, and they precede any meaningful discussion of a dosing timeline.

Tier two: functional exercise-capacity endpoints

Aerobic capacity is the endpoint most closely tied to the "exercise mimetic" label. Researchers reported that SLU-PP-915, an orally active estrogen receptor-related receptor agonist, enhanced aerobic exercise capacity (PMID 41421047). Two qualifications matter for anyone reading that as a timeline. First, SLU-PP-915 is a distinct compound from SLU-PP-332, developed from the same chemical programme; a finding for one analogue is not automatically a finding for the other. Second, the reported outcome is a capacity measurement in a preclinical setting, not a description of subjective effects at a particular week.

Tier three: tissue-level and aging endpoints

The slowest-moving endpoints in this set concern organ biology. A 2023 study in The American Journal of Pathology reported that estrogen-related receptor agonism reversed mitochondrial dysfunction and inflammation in the aging kidney (PMID 37717940). Endpoints of that nature — mitochondrial function and inflammatory signalling in aged tissue — are generally assessed after a treatment interval rather than acutely, which places them at the far end of any measurement sequence.

Why Preclinical Timelines Do Not Convert to Human Weeks

Even where a preclinical study specifies a treatment duration, converting it to a human calendar is not a simple multiplication. Several factors break the conversion:

• Metabolic rate and lifespan scaling. Rodents compress biological processes that unfold over years in humans, so a "long" rodent treatment window may correspond to a very different human interval, in a direction that cannot be assumed.
• Route and exposure. Oral activity was a specific design goal in the analogue work reported in 2026 (PMID 41421047), which underlines that exposure profiles differ between molecules in the same chemical series.
• Endpoint sensitivity. Molecular markers can shift long before any functional measure changes, so a "positive result" at one tier does not imply a visible change at another.
• Model-specific biology. The aging-kidney findings were reported in the context of aged tissue (PMID 37717940), and results from a disease or aging model do not generalise to healthy systems.

The 2026 review's framing of ERRα/β/γ activation as an approach with potential therapeutic applications is consistent with this uncertainty (PMID 42024694).

Adverse Events: What Studies Report

The verified literature summarised here does not present a clinical adverse-event timeline for SLU-PP-332. The papers in this set are a chemical optimization study (PMID 41850449), a pharmacology report on an orally active analogue and aerobic exercise capacity (PMID 41421047), a study of estrogen-related receptor agonism in the aging kidney (PMID 37717940) and a review of ERRα/β/γ activation as an exercise mimetic (PMID 42024694). The absence of human tolerability data in this set is not evidence of safety; it is an absence of data. Nuclear-receptor agonists act on transcriptional programmes distributed across many tissues, which is exactly why regulators require dedicated toxicology and dose-escalation studies before human timelines are discussed at all.

How a Human Timeline Would Have to Be Built

If clinical work on this class proceeds, the measurement sequence would follow a conventional order rather than a consumer-style "week one, week four" schedule:

1. Single-ascending-dose pharmacokinetics, measuring plasma exposure over hours, with safety monitoring as the primary endpoint.
2. Multiple-ascending-dose studies, measuring accumulation and tolerability over days to a few weeks.
3. Short-duration biomarker studies, where transcriptional or metabolic markers are sampled at defined intervals.
4. Functional endpoint trials, in which capacity or performance measures are assessed after a defined treatment period, echoing the aerobic-capacity endpoint researchers used preclinically for the analogue (PMID 41421047).
5. Longer disease-oriented trials, targeting outcomes analogous to the tissue-level changes reported in the aging-kidney work (PMID 37717940).

None of those stages has been published for SLU-PP-332 in the citation set used here, which is why no dated human expectations appear on this page.

Timeline Claims the Literature Does Not Support

Several common framings go beyond what the verified papers state:

• "Effects appear after the first dose." No paper in this set reports a time-to-onset figure for SLU-PP-332 in humans; the aerobic-capacity finding was reported for the analogue SLU-PP-915 in preclinical work (PMID 41421047).
• "Twelve weeks is the standard course." No dosing course of any length is described in the verified set, and the 2026 review characterised the field in terms of potential applications rather than established regimens (PMID 42024694).
• "It works like exercise, so expect exercise-like changes on the same schedule." The exercise-mimetic label describes a mechanistic hypothesis around ERR signaling, as discussed in the chemical optimization work (PMID 41850449), not an equivalence of outcomes or timing.
• "Organ-level benefits are established." The reversal of mitochondrial dysfunction and inflammation was reported in the aging kidney in a 2023 preclinical study (PMID 37717940), which is a model finding, not a clinical outcome.

Reading the Record Honestly

The practical takeaway for a reader trying to understand timing is that the research clock for SLU-PP-332 is currently set at the discovery and preclinical stage. Chemistry work reported insight into estrogen-related receptor signaling (PMID 41850449), analogue pharmacology reported enhanced aerobic exercise capacity (PMID 41421047), a disease-model study reported reversal of mitochondrial dysfunction and inflammation in the aging kidney (PMID 37717940), and a review placed ERRα/β/γ activation in the category of potential therapeutic applications (PMID 42024694). A week-by-week expectation chart cannot be built from that record without inventing numbers.

For background on the compound's mechanism and research context, see the overview page at /learn/slu-pp-332/.

References

• Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney (The American Journal of Pathology, 2023)
• An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (The Journal of Pharmacology and Experimental Therapeutics, 2026)
• Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling (International Journal of Biological Macromolecules, 2026)
• Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications (Revista Médica de Chile, 2026)